Drug Trial Radar · NCT00508924
Study on Safety and Effectiveness of Three Doses of Argatroban as Anticoagulant in Percutaneous Coronary Intervention (PCI)
Last checked: Nov 20, 2026Latest source record: Jan 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
140
Actual
Start
Aug 2005
Primary completion
Not stated
Study completion Oct 2006
Sponsor
- Lead sponsor
- Tanabe Pharma CorporationIndustry
- Sponsor type
- Industry
- First posted
- Jul 30, 2007
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase II multi-centre study in 140 patients undergoing elective PCI to obtain the information on dose-response of argatroban in pharmacodynamic markers and to assess the anticoagulation, safety and efficacy of argatroban in reference to unfractionated heparin, in combination with dual antiplatelet therapy.
Conditions
- Coronary Artery Disease
- Angina, Unstable
Interventions
ArgatrobanDrug
ArgatrobanDrug
ArgatrobanDrug
HeparinDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Activated Clotting Time (ACT) Value After the First Dosing of Study Treatment.Time frame: 5 - 10 min after initial bolus
- Composite and Each of Death, Myocardial Infarction, and Urgent Revascularisation at Day 30, and Major Bleeding Events During Hospital Stay.Time frame: 30 Days
Locations
8 sites in 2 countries. Site status is shown where the registry gives one.
Site not named
Aalst, Belgium
Site not named
Bad Nauheim, Germany
Site not named
Cologne, Germany
Site not named
Dachau, Germany
Site not named
Düren, Germany
Site not named
Frankfurt, Germany
Site not named
Halle, Germany
Site not named
Mainz, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.